

## Special Issue

# Advances of Particle Therapy in Prostate Cancer

### Message from the Guest Editor

Prostate cancer is the most prevalent cancer among men in the United States. Radiation therapy has been one of the major treatment options for prostate cancer. Recent technical advances in external beam RT using photons—for example, SBRT and IMRT—have permitted the delivery of a higher dose to tumors and a lower dose to surrounding tissues. At the same time, basic and clinical research into external RT using particles (particle RT) has been carried out for the purpose of establishing more effective and non-invasive treatments. Among the particles used in such treatments, protons and carbon ions are the ones most commonly used. New technologies and clinical approaches have been developed to improve therapies. This Special Issue aims to introduce recent advances and breakthroughs in the particle treatment of prostate cancer. Submissions of communications, full papers, mini-reviews, and reviews are all welcomed. We look forward to your contributions and fruitful discussions.

---

### Guest Editor

Dr. Xinning Wang

Department of Biomedical Engineering, Case School of Engineering,  
Case Western Reserve University, Cleveland, OH, USA

---

### Deadline for manuscript submissions

closed (10 September 2024)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/si/164411](https://mdpi.com/si/164411)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)